Allergy Therapeutics (AGY) Competitors GBX 8.30 +0.10 (+1.22%) As of 09/18/2025 11:55 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock AGY vs. AMYT, APH, BXP, ANCR, STX, VLG, EAH, DNL, PXS, and CHLLShould you be buying Allergy Therapeutics stock or one of its competitors? The main competitors of Allergy Therapeutics include Amryt Pharma (AMYT), Alliance Pharma (APH), Beximco Pharmaceuticals (BXP), Animalcare Group (ANCR), Shield Therapeutics (STX), Venture Life Group (VLG), ECO Animal Health Group (EAH), Diurnal Group (DNL), Provexis (PXS), and Chill Brands Group (CHLL). These companies are all part of the "drug manufacturers - specialty & generic" industry. Allergy Therapeutics vs. Its Competitors Amryt Pharma Alliance Pharma Beximco Pharmaceuticals Animalcare Group Shield Therapeutics Venture Life Group ECO Animal Health Group Diurnal Group Provexis Chill Brands Group Amryt Pharma (LON:AMYT) and Allergy Therapeutics (LON:AGY) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership. Is AMYT or AGY more profitable? Amryt Pharma has a net margin of 0.00% compared to Allergy Therapeutics' net margin of -72.86%. Amryt Pharma's return on equity of 0.00% beat Allergy Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Amryt PharmaN/A N/A N/A Allergy Therapeutics -72.86%-266.59%-34.76% Do institutionals and insiders have more ownership in AMYT or AGY? 5.9% of Allergy Therapeutics shares are owned by institutional investors. 4.7% of Allergy Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has better valuation & earnings, AMYT or AGY? Amryt Pharma has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Amryt Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmryt Pharma£210.24M0.00N/A-£33.00N/AAllergy Therapeutics£55.66M7.11-£52.59M-£0.01-1,152.78 Does the media prefer AMYT or AGY? In the previous week, Amryt Pharma's average media sentiment score of 0.00 equaled Allergy Therapeutics'average media sentiment score. Company Overall Sentiment Amryt Pharma Neutral Allergy Therapeutics Neutral SummaryAmryt Pharma beats Allergy Therapeutics on 5 of the 8 factors compared between the two stocks. Get Allergy Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AGY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AGY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AGY vs. The Competition Export to ExcelMetricAllergy TherapeuticsDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£395.62M£1.67B£5.77B£2.57BDividend Yield8.33%2.94%5.74%5.31%P/E Ratio-1,152.7869.6876.865,427.87Price / Sales7.111,210.95544.1397,460.80Price / Cash3.6610.3737.1727.93Price / Book84.1111.7113.839.27Net Income-£52.59M£20.70B£3.29B£5.89B7 Day PerformanceN/A0.04%1.57%0.58%1 Month Performance-4.60%1.81%6.86%3.21%1 Year Performance74.74%4.70%81.58%186.69% Allergy Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AGYAllergy TherapeuticsN/AGBX 8.30+1.2%N/A+93.0%£395.62M£55.66M-1,152.78612AMYTAmryt PharmaN/AN/AN/AN/A£457.11M£210.24M-4.33290Gap DownAPHAlliance Pharma1.9152 of 5 starsGBX 64.70flatGBX 6,250+9,560.0%N/A£350.32M£183.50M-10.4391,000BXPBeximco PharmaceuticalsN/AGBX 45-3.2%N/A+114.3%£200.75M£46.34B3.165,500Gap DownANCRAnimalcare GroupN/AGBX 249.50+0.2%N/A+3.1%£172.13M£74.23M834.45220News CoverageSTXShield Therapeutics1.6558 of 5 starsGBX 9.35+14.0%N/A+92.0%£97.40M£41.50M-467.5040,000Analyst ForecastGap UpHigh Trading VolumeVLGVenture Life GroupN/AGBX 57.24-3.0%N/A+18.8%£73.29M£26.59M-22,894.00165Gap UpEAHECO Animal Health Group2.7894 of 5 starsGBX 73.55+0.1%GBX 150+103.9%-19.6%£49.64M£79.60M3,026.75234News CoverageDNLDiurnal GroupN/AN/AN/AN/A£46.33M£4.68M-3.2133PXSProvexisN/AGBX 0.64-4.2%N/A+14.4%£15.01M£1.20M-2,133.334Gap UpCHLLChill Brands GroupN/AGBX 2flatN/AN/A£10.13M£305.70K-307.697 Related Companies and Tools Related Companies AMYT Competitors APH Competitors BXP Competitors ANCR Competitors STX Competitors VLG Competitors EAH Competitors DNL Competitors PXS Competitors CHLL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:AGY) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredThis is the “End of Tesla” as we know it…Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allergy Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Allergy Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AGY Stock Alerts